文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

特发性难治性重型再生障碍性贫血患者的非血缘脐血移植:一项全国性2期研究

Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study.
PubMed 文献 · Blood · 2018-05-14

该前瞻性全国2期研究评估非血缘脐血移植治疗难治性重型再生障碍性贫血的疗效与安全性,纳入26例患者(中位年龄16岁),1年总生存率88.5%,显著高于预设20%的无效假设(P < .0001),2年总生存率84%。

要点

  • 难治性重型再生障碍性贫血患者接受非血缘脐血移植后1年总生存率达88.5%。
  • 植入率为88%,II-IV级急性移植物抗宿主病累积发生率为45.8%,慢性移植物抗宿主病累积发生率为36%。
  • 含≥4×10^7冻存有核细胞/千克的脐血单位是年轻难治性重型再生障碍性贫血患者的潜在治愈选择。

核心结论

  • 含≥4×10^7冻存有核细胞/千克的脐血单位移植是年轻难治性重型再生障碍性贫血且无相合非血缘供者患者的有价值治愈选择。

研究设计与样本

  • 前瞻性全国2期研究(再生障碍性贫血与脐血移植方案),纳入26例难治性重型再生障碍性贫血患者,中位年龄16岁。
  • 为证明1年生存率从20%(无效假设)提高至50%(备择假设)的显著差异,需纳入25例移植患者,实际纳入26例。
  • 入组标准要求1或2份非血缘脐血单位,单独或合计含>4×10^7冻存有核细胞/千克受者体重。
  • 预处理方案包括氟达拉滨(FLU)、环磷酰胺(CY)、抗胸腺细胞球蛋白(ATG)和2 Gy全身照射(TBI)。
  • 试验注册号:NCT01343953。

主要发现

  • 中位随访38.8个月,23例患者(88%)实现植入。
  • II-IV级急性移植物抗宿主病累积发生率为45.8%,慢性移植物抗宿主病累积发生率为36%。
  • 1年时23例患者存活,总生存率88.5%,与预期的20%存在显著差异(P < .0001);2年总生存率为84%。

关键数值与推荐

  • 脐血单位要求:单独或合计含>4×10^7冻存有核细胞/千克受者体重。
  • 预处理方案:氟达拉滨(FLU)、环磷酰胺(CY)、抗胸腺细胞球蛋白(ATG)和2 Gy全身照射(TBI)。

临床怎么用

  • 作者认为,含≥4×10^7冻存有核细胞/千克的脐血移植是年轻难治性重型再生障碍性贫血且无相合非血缘供者患者的有价值治愈选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes remain poor for refractory severe aplastic anemia (SAA) patients. Alternative donor transplantation may be considered, but results from previous studies are not encouraging. We conducted a prospective nationwide phase 2 study to assess unrelated cord blood (CB) transplantation (CBT) efficacy and safety in refractory SAA patients (Aplastic Anemia and Cord Blood Transplantation protocol). To demonstrate a significant difference in 1-year survival from 20% (null hypothesis) to 50% (alternative hypothesis), we needed to include 25 transplanted patients and therefore included 26 (median age, 16 years). Eligibility criteria required 1 or 2 unrelated CB units, containing separately or together >4 × 107 frozen nucleated cells (NCs) per kilogram of recipient body weight. Conditioning regimen comprised fludarabine (FLU), cyclophosphamide (CY), antithymocyte globulin (ATG), and 2-Gy total body irradiation (TBI). With a median follow-up of 38.8 months, engraftment occurred in 23 patients (88%); cumulative incidences of grade II-IV acute and chronic graft-versus-host disease were 45.8% and 36%, respectively. Twenty-three patients were alive at 1 year, with an 88.5% overall survival (OS) rate, differing significantly from the expected 20% (P < .0001; 84% OS at 2 years). CBT with units containing ≥4 × 107 frozen NCs per kilogram is therefore a valuable curative option for young adults with refractory SAA and no available matched unrelated donors. This trial was registered at www.clinicaltrials.gov as #NCT01343953.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018. PMID: 29760162. doi:10.1182/blood-2018-01-829630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。